Poof! No More Odor, No More Pollutants? BioLargo Inc. Is Doing Its Best To Make It So (Benzinga interview)

Source: Benzinga (https://www.benzinga.com/markets/penny-stocks/22/12/30056138/poof-no-more-odor-no-more-pollutants-biolargo-inc-is-doing-its-best-to-make-it-so)

Dennis Calvert, CEO of BioLargo, Inc. (BLGO), was a guest on Benzinga’s All Access on 12/9/22.

BioLargo is a cleantech company that develops and commercializes advanced technology that “makes life better”. The company has 8 fully developed platform technologies with more in development. Its PFAS technology is capable of cleaning water systems of the harmful “forever chemicals” that have leached into almost all water in the world. Another of its technologies has been formulated into an eco-friendly, non-toxic odor eliminating spray that is currently gaining steam in sales.

Watch the full interview here:

BioLargo’s Partner Ikigai Begins Sales of Pooph at Walmart

Pooph: The Pet Odor Remover that Takes Stink Out of the Equation  

Westminster, CA – November 22, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, is pleased to announce that the Pooph™ pet odor control product line is now available at select Walmart stores.

Pooph, which is based on BioLargo’s proprietary odor control technology, is marketed by Ikigai Marketing Works, LLC through a national advertising campaign (see www.Pooph.com). Walmart is the first retailer for a planned national retail distribution, and begins with Pooph in over 600 stores across the United States.

Jane Pak, CEO of Ikigai commented, “Sales of Pooph have exceeded our expectations and forecasting. Availability of Pooph at 681 Walmart stores is just the beginning of what we expect to be national retail distribution. The team at BioLargo have been great at supporting our success. Our team is excited to continue watching Pooph become solidified as a nationally known and trusted consumer packaged goods brand.” 

Dennis P. Calvert, President and CEO of BioLargo said, “The team at Ikigai has continued to grow sales and brand awareness with its highly effective marketing that showcases the product’s complete and rapid odor elimination, and its safety.  We are thankful for the very talented team at Ikigai and look forward to working closely with them to support their continued expansion.”

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo: This Company is Helping Keep The Earth Clean (Benzinga Interview)

Dennis Calvert, President & CEO of BioLargo, Inc. (BLGO) was a guest on Benzinga’s All Access on Nov 18, 2022.

BioLargo invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. 

Watch the full interview here:

Sequire Spotlight Presents Biolargo (BLGO): An Innovator & Solution Provider For a Clean Environment

Host Jonathan Miller interviews CEO: Dennis Calvert. He states that the culture of service is what brings a good service to the table when it comes to saving our natural resources.

BioLargo Achieves 111% Growth to a Record $1.5 Million Revenue for Third Quarter 2022

Conference call scheduled for Wednesday, November 16 at 5:00 pm Eastern

Westminster, CA – November 15, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, filed its Quarterly Report on Form 10-Q for the three months and nine months ended September 30, 2022, with the SEC yesterday (www.biolargo.com/sec-filings). Here the company has provided highlights from the quarterly report and a discussion of key business initiatives with the most potential to stimulate growth.

The company will hold an investor webcast on Wednesday, November 16, 2022, at 2:00 pm Pacific / 5:00 pm Eastern, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/47095

BioLargo’s President and CEO Dennis P. Calvert said, “In this quarter we again broke our quarterly revenue record, and have already far surpassed 2021’s total revenues. Our strategy of growing by leveraging our core technology assets through channel partnerships is paying off, as evidenced by the growing success of our pet odor control product partnership. We also expect the commercial roll-out of our PFAS treatment system to play a big role in the future growth of our company.”

Financial highlights

• Company-wide consolidated revenue for the three and nine months ended September 30, 2022, was $1,500,000 and $3,786,000, which is a 111% and 117% increase over the same periods in 2021; revenue this quarter was a 13% increase compared with the second quarter of 2022.
• Revenues from ONM Environmental, the company’s odor and VOC control subsidiary, for the three and nine months ended September 30, 2022, were $1,199,000 and $2,499,000, an increase of $779,000 and $1,441,000, from the same periods in 2021. In the third quarter of 2022, this subsidiary generated operating income of $400,000, compared to an operating loss of $72,000 in the same period of 2021.
• Revenues from third parties for BioLargo Engineering, Science & Technologies, the company’s environmental engineering subsidiary, for the three and nine months ended September 30, 2022, were $283,000 and $1,254,000, an increase of $2,000 and $699,000, from the same periods in 2021.

Commercial highlights

• Sales of the Pooph branded pet odor control product to Ikigai have risen significantly, accounting for the bulk of the rise in revenue at ONM Environmental. Ikigai intends to continue their national advertising campaign as the product is launched in Walmart and other national retailers.
• The company secured its first customer to engineer a comprehensive PFAS mitigation plan for a large industrial site. The project’s first phase, the development of a comprehensive PFAS treatment plan, is underway, and subsequent phases are expected to advance in the coming months.
• The company’s plans to roll out its PFAS treatment technology across the country progressed significantly, with the securing of Product Recovery Management as a contract manufacturer, and a growing number of sales representative organizations that are expected to cover most of North America.
• BioLargo’s engineering division completed the first phase of some large projects, including the waste-to-energy conversion plant project in South America and the fuel production system project with Ultra Safe Nuclear. Both projects are anticipated to advance to subsequent phases which are of greater scope in the coming months.
• The company added two new board members to its team: Linda Park and Christina Bray. Both new board members have a background, education, and corporate experience that make them an ideal fit to advance BioLargo’s core organizational goals, and its vision to “make life better” through its cleantech products and services.
• BioLargo Engineering, Science & Technologies built field units of its PFAS treatment technology the Aqueous Electrostatic Concentrator (AEC) to be used in trial projects whereby customers try out the technology, for a fee, to ensure it accomplishes their water treatment goals and assists them in meeting new water standards for PFAS. Learn more about the company’s PFAS Testing Program (the company’s piloting program) at https://www.biolargoengineering.com/biolargo-pfas-testing-program/.

Correction: an earlier version of this release incorrectly stated, under Financial Highlights, that ONM Environmental generated operating income of $400,000 in the second quarter of 2022. In this corrected version, we state that ONM Environmental generated operating income of $400,000 in the third quarter of 2022 (the quarter being reported on in today's release).

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.biolargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as “we believe”. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo Q3 2022 Earnings Results Webcast and Conference Call on Wednesday, November 16, 2022 - 5 PM Eastern Time

Westminster, CA – November 10, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced it will host an investor webcast and conference call on Wednesday, November 16, 2022, at 2:00 pm Pacific / 5:00 pm Eastern. The event, which will be open to the public, will be held to review the company’s financial results for the three and nine months ended September 30, 2022, discuss recent milestones, and conduct a question-and-answer session.

To listen to a live broadcast, go to the site linked below at least 15 minutes prior to the scheduled start time to register and download any necessary audio/video software.

To participate in the live webcast and teleconference:

Webcast Link: https://www.webcaster4.com/Webcast/Page/2448/47095 

Teleconference Domestic:                888-506-0062

Teleconference International:         973-528-0011

Participant Access Code:                796301

To watch or listen to a replay of the webcast or teleconference:

Webcast Replay Expiration:             Friday, November 17, 2023

Teleconference Replay Expiration:     Thursday, November 30, 2022

Teleconference Replay Domestic:     877-481-4010

Teleconference Replay International:     919-882-2331

Replay Passcode:                                      47095

The webcast replay and accompanying presentation materials will be made available on the Investor Relations section of BioLargo’s website at www.biolargo.com/investor-relations. 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.  

Contact Information

Dennis P. Calvert 

President and CEO, BioLargo, Inc. 

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Results from BioLargo’s 18-Month Municipal Wastewater Treatment Pilot in Montreal Presented at National Conference

Westminster, CA – November 8, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced that its subsidiary BioLargo Water presented the results of its municipal wastewater treatment pilot at the Canadian Water and Wastewater Association’s annual conference in Halifax, Nova Scotia. Results presented at the conference cement the company’s patented Advanced Oxidation System (AOS) water treatment technology as a powerful yet energy- and cost-efficient solution for removing emerging contaminants from wastewater.

In the face of an expanding population, aging sewage treatment infrastructure, and the growing concern of hard-to-treat wastewater contaminants like pharmaceuticals (a.k.a., “micropollutants”, identified by the US EPA as “contaminants of emerging concern”), there is a growing global interest in new water treatment technologies that can effectively and affordably remove a broad spectrum of water contaminants while also addressing legacy contaminants like bacteria and viruses.

BioLargo developed its AOS to be the new gold standard technology for tertiary wastewater treatment (i.e., the final step in sewage treatment). The AOS uses proprietary electro-oxidation technology to generate a blend of powerful iodine molecules and hydroxyl radicals inside its patented reaction cell, resulting in rapid and energy-efficient water disinfection and breakdown of organic contaminants.

A commercial-scale AOS unit has been operating, continuously, on-site at a municipal wastewater treatment plant pilot site at a municipality near Montreal, Quebec, for the past 18 months. The purpose of the pilot was to test whether the AOS could remove certain pharmaceutical micropollutants from the municipality’s wastewater more effectively than the plant’s current equipment, as well as to verify that the AOS could operate in a real-world wastewater treatment plant over long periods of time without issue.

Over the course of the pilot, the AOS system significantly improved removal of pharmaceuticals from the plant’s municipal wastewater. Currently, the treatment plant (which does not include any equipment specifically designed for pharmaceutical removal) is able to remove only a portion of each of the targeted contaminants. When the AOS was added to the treatment train, removal efficiency increased to between 84% and 100% (depending on the particular targeted contaminant).

On November 7, 2022, BioLargo Water’s Lead Research Scientist Dr. Laura Patterson-Fortin presented the results of the municipal wastewater treatment pilot at the Canadian Water and Wastewater Association’s flagship annual event, the National Water and Wastewater Conference, in Halifax, Nova Scotia. Dr. Patterson-Fortin presented these results alongside the company’s academic partners from the world-renowned Centre des Technologies de l’Eau (CTE) in Montreal, who oversaw the pilot project’s operation and analyzed its results.

Dr. Richard Smith, President of BioLargo Water, commented, “The AOS is a truly remarkable water treatment technology on the cutting edge of micropollutant treatment. While their regulatory status in the US and Canada is still in the early stages, micropollutants are garnering the attention of regulators in Europe due to their potential to cause environmental damage and affect human health. Many of the leading companies in the water industry have identified micropollutants as a driver for future growth. We intend for the AOS to be ahead of the curve as an effective, energy-efficient option for micropollutant treatment as this market develops globally.”

He continued, “If all the AOS could do was remove pharmaceuticals from wastewater, it would have a bright commercial future as governments around the world adopt new regulations. But the AOS does much more than that – it is also a highly effective, affordable, and energy-efficient water disinfection device that rivals UV – making it deliver exceptional value to wastewater treatment operators seeking to future-proof their operations.”

BioLargo Adds Linda Park and Christina Bray to Board of Directors

Westminster, CA – November 3, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced it has added two new board members to its team: Linda Park and Christina Bray. Both new board members have a background, education, and corporate experience that make them an ideal fit to advance BioLargo’s core organizational goals, and its vision to “make life better” through its cleantech products and services.

Linda Park is a trusted executive and legal professional with a proven track record of supporting and advising public companies. With corporate board and executive experience at billion-dollar corporations such as her current roles working with Edward Lifesciences in her capacity as Corporate Secretary, Senior Vice President and Associate General Counsel, and Board Member of the Edwards Lifesciences Foundation, and prior work with Western Digital Corporation, Linda brings over 20 years of experience advancing organizations’ corporate governance and strategic goals. She also has many years of experience advising issuer and investment banking clients on corporate and securities matters, mergers and acquisitions, bank financings and capital markets, including initial public offerings. She is also an active partner and thought leader on environmental, social, and corporate governance issues. Linda has an undergraduate degree from Johns Hopkins University, and a law degree from Duke University School of Law.

Christina Bray is a senior finance specialist, entrepreneur, and renewables specialist, and currently serves as the CEO and founder of Bluedot Energies, an innovative company that designs, builds, and manages electric vehicle charging stations for large-scale public and private applications. A rising star in green energy technologies, Christina has significant finance, capital projects, and corporate operation experience, having negotiated M&A activities and managed $1 billion in quarterly loan volume at the solar fintech company Sunlight Financial. She has extensive training including a master’s degree in Military History from Norwich University and an undergraduate degree in Middle Eastern Studies from Yale University. She is well-versed in middle eastern language and society.

“We are so pleased that Linda Park and Christina Bray have joined our Board of Directors,” said Dennis P. Calvert, BioLargo’s CEO. “Both have such significant experience in advancing innovative projects, as well as building and supporting successful companies. We know that they will make important contributions to our efforts to transform BioLargo into a cleantech juggernaut. With Linda and Christina on board, we couldn’t be more confident in the future for our company.”

Concurrently, board members John S. Runyan and Kent C. (Rick) Roberts II have retired from their positions on the Board of Directors where they served faithfully for over a decade. Both will remain as formal Advisors to the Board of Directors as their time permits.

Mr. Calvert commented, “John and Rick have made significant contributions to the company over the years, and we are thankful for their meaningful impact on the company. We look forward to working with them in the future in their roles as Advisors to the board.”

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as “we believe”. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo Presentation from LD Micro Main Event XV in October, 2022

BioLargo President and CEO Dennis P. Calvert presented the company's business model of inventing, developing, and commercializing best-in-class environmental technologies at this year's LD Micro Main Event in Los Angeles, California. 

You can review the company's investor pitch deck right here:

Proactive Investors Interview: BioLargo says it is just scratching the surface of commercial opportunities as revenue surges

Source: Proactive Investors (https://www.proactiveinvestors.com/companies/news/996861/biolargo-says-it-is-just-scratching-the-surface-of-commercial-opportunities-as-revenue-surges-996861.html?viewSource=TwitterUS) 

BioLargo Inc (OTCQB:BLGO) CEO Dennis Calvert tells Proactive's Stephen Gunnion that the company is just scratching the surface of commercial opportunities for its technology as momentum continues to build.

The cleantech group reported third-quarter revenue of about $1.5 million, a 13% increase from Q2 and a 111% increase on Q3, 2021.

Calvert said BioLargo's POOPH pet odor control product and its PFAS removal project will contribute to growing revenues in Q4 and going into 2024, while other projects will also support growth.

BioLargo Sets Another New Quarterly Revenue Record

Westminster, CA – October 26, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, today announced that it has set a new quarterly revenue record, and provided a snapshot of continued business developments.

BioLargo’s President and CEO Dennis P. Calvert commented, “It is remarkable that we were able to improve on Q2’s record-breaking results, and that because of our Q3 performance we have also locked in a record growth rate for the entire year. We are proud of these accomplishments, but not yet satisfied because we believe that we have still just scratched the surface of the commercial opportunities ahead. We intend to continue this trend of meaningful growth, and we are already off to a good start in Q4.”

The company has several key projects that management believes will stimulate accelerated growth through 2023. These are:

• The expected launch in major retailers of the POOPH pet odor control product by the company’s consumer packaged goods partners at Ikigai, which is expected to start in Q4.
• Our first PFAS removal project at a large industrial site (announced in August), currently in the initial phase of a multi-phase process, which we expect to continue advancing as we engineer a comprehensive PFAS mitigation plan.
• Expanded commercial roll-out of the company’s PFAS treatment technology through its growing network of sales rep organizations.
• Garratt-Callahan’s launch of the jointly developed minimal liquid discharge wastewater treatment product.               
• Further work on larger engineering projects, including the waste-to-energy conversion plant project in South America, and the company’s work with Ultra Safe Nuclear.

BioLargo generated approximately $1.5 million in company-wide revenue during the third quarter of 2022, representing a 13% increase compared with the second quarter of 2022, and a 111% increase compared with the third quarter of 2021, led by a significant increase in sales of the POOPH pet odor product. Note, however, that these revenue figures are preliminary, and are subject to change pending review by the company's independent registered public accounting firm. The company will include its full results of operations in its quarterly report for the period ended September 30, 2022, due to be filed with the SEC by November 14, 2022. The company also intends to hold an investor webcast and conference call shortly after the filing of its quarterly report to discuss its financial results, and will provide details for participating in this event as soon as they are available.

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as “we believe”. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo, Inc. Discusses Its PFAS Treatment Solution and Odor Control Technology with The Stock Day Podcast

Source: https://www.newsfilecorp.com/release/141860 

Phoenix, Arizona--(Newsfile Corp. - October 25, 2022) - The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB: BLGO), a company that invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. CEO of BioLargo, Dennis Calvert, joined Stock Day host Everett Jolly.

Jolly began the interview by asking about BioLargo's PFAS treatment technology. Calvert explained the origins of PFAS contamination and how it threatens water around the world. "These forever chemicals can lead to adverse health effects, birth defects, cancer, and all sorts of incredibly negative illnesses, with litigations happening all over the world," explained Calvert.

Calvert then discussed the challenges with current PFAS treatment solutions, which typically generate significant waste, creating an environmental hazard. In contrast, BioLargo's own treatment solution the Aqueous Electrostatic Concentrator (AEC) generates very little solid waste, making it both eco-friendly and logistically sound for customers.

"What is your roll out plan?", asked Jolly. Calvert explained that the company has several channel partners already on board to represent the AEC, and that several additional sales rep organizations have indicated they would also carry the AEC after discussions at recent trade shows. "We have shored up outsourced manufacturing with PRM [(Product Recovery Management)], which gives us the ability to be able to deliver machines and equipment to scale rapidly to combine with our own."

The conversation then turned to BioLargo's pet odor technology. "We have negotiated an arrangement with our partner where we have a cost plus arrangement," said Calvert. "We also [would] participate in the equity of the brand upon exit, equal to 20%," he continued. "That product is now doing over $100,000 per day in sales, which was a significant revenue contribution to our record performance last quarter," he shared. "They are ramping up, and are expecting to enter Walmart stores in November," said Calvert, adding that the company expects these sales to reflect in the fourth quarter and anticipates more major retailers coming onboard.

To close the interview, Calvert elaborated on BioLargo's significant potential as they continue to find adoption for their growing technology solutions. He also encouraged listeners to keep up-to-date on their current and upcoming projects by following the company's blog at https://biolargo.blogspot.com/.

To hear Dennis Calvert's entire interview, follow the link to the podcast here: https://audioboom.com/posts/8180691-biolargo-inc-discusses-its-pfas-treatment-solution-and-odor-control-technology-with-the-stock-d

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/

About BioLargo, Inc.

BioLargo, Inc. (OTCQB: BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as "we believe". These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.

SOURCE:
Stock Day Media
(602) 821-1102

Benzinga Interview: Meet The Company On The Front Lines Of The Fight To Keep The Planet Green

 Source: Benzinga (https://www.benzinga.com/markets/penny-stocks/22/10/29397796/meet-the-company-on-the-front-lines-of-the-fight-to-keep-the-planet-green) 

Dennis Calvert, CEO of BioLargo Inc (BLGO), was a guest on Benzinga’s All Access on October 21, 2022.

BioLargo invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. The company recently achieved 185% growth in Q2 2022, reaching  $1.3 Million in revenue.

Watch the full interview here:

Tonya Chandler's PFAS Webinar in Wisconsin

BioLargo's Director of Commercialization Tonya Chandler has been doing a circuit of presentations to engineers around the country about the state and evolution of the PFAS treatment market. 

This webinar presentation was delivered to a group of engineers in Wisconsin late last month, and is now available to watch right here on our blog. Watch to learn about changes to state limits, federal limits, and PFAS' evolving status as a hazardous substance under CERCLA/RCRA.

BioLargo’s WEFTEC 2022 Recap

Source: ntradeshows.com

As WEFTEC week comes to close, we reflect on the success of this important conference this year. The BioLargo team came out in force, showing off our sustainable PFAS treatment technology, our cost-effective, low-energy wastewater disinfection and micropollutant removal technology the AOS, and our industry-leading odor and VOC control products.

Our room at the conference hosted an endless stream of technical experts, sales reps, engineers, and other conference attendees, each of whom checked out the demo units for our water treatment technologies!

Representatives from the EPA, which is hard at work shaping regulations for PFAS contaminated water, came to check out and discuss our innovative low-waste PFAS system. We gave interviews for several water sector media outlets including GWI and Water Online (which will be available soon!). We also received verbal commitments from multiple sales representative groups interested in carrying our treatment systems.

A special shout-out to our partners at Garratt-Callahan, with whom we are co-commercializing a new Minimal Liquid Discharge (MLD) wastewater treatment system. We had some great and promising strategy meetings surrounding our customer roll-out plans for this technology at the conference, and we’re more excited than ever for the prospects of this partnership.

Thank you to the hard-working WEFTEC staff for putting on such an excellent event this year. It truly is the best opportunity to develop all-important relationships and advance strategic goals in the water sector.

BioLargo Secures Product Recovery Management (PRM) as Channel Partner and Contract Manufacturer for BioLargo’s Water Treatment Technologies

Westminster, CA – October 6, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced that it signed a channel partnership agreement with Product Recovery Management, Inc. to sell and distribute BioLargo’s water treatment systems and act as a contract manufacturer.

Product Recovery Management (PRM) (https://www.prmfiltration.com/), based out of Butner, NC, is a UL-certified equipment integrator specializing in remediation services with over 40 years of history serving customers. PRM designs and manufactures treatment systems that address a wide variety of contamination challenges in the remediation and landfill industries, including PFAS contamination. Their Butner operations include a 250,000 square foot manufacturing facility with large-scale fabrication capabilities.

The channel partner agreement grants PRM a license to sell and distribute BioLargo’s innovative water and wastewater treatment technologies, including but not limited to the Aqueous Electrostatic Concentrator (AEC), BioLargo’s effective, affordable, low-waste solution for removing per- and polyfluoroalkyl substances (PFAS) from water. PRM will also be authorized to sell BioLargo’s Advanced Oxidation System (AOS) technology, the energy-efficient and affordable solution for simultaneous water disinfection and micropollutant treatment.

PRM will also be a contract manufacturer for BioLargo’s water treatment technologies, including the AEC, the AOS, as well as other treatment systems designed by BioLargo (e.g., reverse osmosis systems).

“PRM has substantial expertise and infrastructure to support the roll-out and manufacturing of our cleantech systems. This relationship will allow us to more readily meet the growing demand for our systems and expand our reach into the market. We have already begun scoping our first project together,” says Randall Moore, President of BioLargo Engineering, Science & Technologies (BioLargo’s engineering subsidiary – www.BioLargoEngineering.com).

“BioLargo’s AEC and AOS technologies are unique and valuable tools for targeted removal of tough-to-treat water contaminants including PFAS and micropollutants, both of which currently lack effective and affordable options in the marketplace. We recognized in BioLargo a commitment to serve customers with technical excellence and reliable results. We look forward to working with the BioLargo team,” said Robert Phillips, Jr., President of Product Recovery Management.

 

About PRM:

Headquartered in Butner, NC. PRM was founded in 1990 by Mel and Brian Phillips. Originating as Phillips Electric Company in 1976, PRM is now a premier environmental remediation and landfill gas company with systems operating across the globe. PRM is an Original Equipment Manufacturer (OEM) of pollution control and other equipment, mainly focused on the Remediation and Landfill Industries. Their experiences and talents are well diversified.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as “we believe”. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo Launches New Website To Highlight PFAS Mitigation Solutions

Source - Water Online: https://www.wateronline.com/doc/biolargo-launches-new-website-to-highlight-pfas-mitigation-solutions-0001 

BioLargo, Inc., developer of innovative cleantech technologies that target tough water and air contamination challenges, has launched a new website to promote its line of systems and services that tackle water contaminated by per- and polyfluoroalkyl substances (PFAS). The company also announced that it will be available to discuss its PFAS mitigation tools with prospective customers and distributors at the upcoming WEFTEC conference and trade show in New Orleans from October 8-12, 2022.

PFAS are an expansive class of man-made chemicals that contaminate thousands of drinking water sources around the US, with links to numerous negative health effects including cancer, hormone dysfunction, developmental disorders, and more. Due to their extremely stable chemical structure, PFAS do not break down naturally in the environment or in humans, causing them to bioaccumulate and inflict health impacts slowly over time. Another consequence of their stability is that there are few effective tools for removing them from water and wastewater.

BioLargo developed its own treatment technology to remove PFAS from water and started the commercialization process last October. Its system, called the Aqueous Electrostatic Concentrator (AEC), works by separating PFAS compounds in an electric field and depositing them onto proprietary membranes. It has been proven to remove a wide number of PFAS compounds to below the level of detection, consuming as little as 30 cents per 1,000 gallons in electricity costs. Crucially, the AEC generates as little as 1/1000 the PFAS-laden solid waste compared to other treatment options like carbon filtration and ion exchange, making it a low-carbon treatment option for eco-conscious treatment operations.

BioLargo’s new website, https://www.bestpfastreatment.com/, highlights the AEC and BioLargo’s other PFAS mitigation solutions, including its PFAS testing program (a way to quickly and affordably determine a site’s PFAS contamination levels and appropriate treatment solutions). It also offers insights into its broader environmental engineering and system integration services.

The website aims to become an educational resource for industry users by hosting educational articles on PFAS contamination, which is an ever-evolving issue with complex regulatory and techno-economic considerations that shift nearly every week.

“Our goal is to become a resource for those facing PFAS issues,” says Tonya Chandler, Director of Commercialization for BioLargo, Inc. “The landscape of PFAS regulations and mitigation technologies changes day by day. We wanted to offer a place where the industry could learn more about PFAS and how to remove it.”

BioLargo staff will be attending WEFTEC, the foremost water and wastewater sector conference and trade show in New Orleans from October 8-12, 2022. They will be available to discuss PFAS, the AEC and the company’s other solutions . Interested parties in attendance are encouraged to reach out to BioLargo to arrange meetings using the following contact information:

Tonya Chandler, Director of Commercialization
Email: Tonya.chandler@biolargo.com
Phone: +1-608-397-8301

Clean Air Through Clean Tech: Meet This Environmental Guardian (Benzinga Interview)

Source: Benzinga (https://www.benzinga.com/markets/penny-stocks/22/09/28863842/clean-air-through-clean-tech-meet-this-environmental-guardian)

Dennis Calvert, CEO of BioLargo, Inc. (BLGO), was a guest on Benzinga’s All Access on September 12, 2022 .

BioLargo is an environmental engineering and solutions provider. The company develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control.

Watch the full interview here:

BioLargo sees 'a major opportunity' for PFAS unit as it reports a surge in second-quarter revenue

Source: Proactive Investors (https://www.proactiveinvestors.ca/companies/news/990601/biolargo-sees-a-major-opportunity-for-pfas-unit-as-it-reports-a-surge-in-second-quarter-revenue-990601.html) 

BioLargo Inc (OTCQB:BLGO) CEO Dennis Calvert takes Proactive's Stephen Gunnion through the company's second-quarter results, which show a 185% year-over-year jump in revenue to $1.32 million on the back of strong contributions from its engineering and environmental divisions.

Calvert telling Proactive that the company's PFAS (per- and polyfluoroalkyl substances) business is a major opportunity, and BioLargo is at the forefront of real environmental impact, working with channel partners to solve some of today’s toughest environmental challenges.

BioLargo Achieves 185% Growth to $1.3 Million Revenue for Second Quarter 2022, as Published in Quarterly Report

Quarterly Report highlighted by profitable operating subsidiaries, growth of white-label odor product sales, and large engineering projects

Westminster, CA – August 16, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, filed its Quarterly Report on Form 10-Q for the period ended June 30, 2022, with the SEC yesterday (www.biolargo.com/sec-filings). Here the company has provided highlights from the quarterly report and a discussion of key business initiatives with the most potential to stimulate growth.

The company will hold an investor webcast on Wednesday, August 17, 2022, at 1:00 pm Pacific / 4:00 pm Eastern, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/46358

BioLargo’s President and CEO Dennis P. Calvert said, “We are proud of the entire BioLargo team working together and executing on all fronts as we continue growing the business through bigger and better projects. It has been incredible to watch our team land and expand into new client projects through great service and deliverables. PFAS is a major opportunity for us, and we are on the forefront of real environmental impact, working with channel partners to solve some of today’s toughest environmental challenges.”

Financial highlights

• Company-wide consolidated revenue for the three and six months ended June 30, 2022, was $1,323,000 and $2,287,000, which is a 185% and 121% increase over the same periods in 2021; revenue this quarter was a 37% increase compared with the first quarter of 2022.
• Revenues from ONM Environmental, the company’s odor and VOC control subsidiary, for the three and six months ended June 30, 2022, were $700,000 and $1,300,000, an increase of $344,000 and $658,000, from the same periods in 2021. In the second quarter of 2022, this subsidiary generated a net operating income of $11,000, compared to a net operating loss of $107,000 in the same period of 2021.
• Revenues from third parties for BioLargo Engineering, Science & Technologies, the company’s environmental engineering subsidiary, for the three and six months ended June 30, 2022, were $617,000 and $972,000, an increase of $434,000 and $698,000, from the same periods in 2021. In the second quarter of 2022, this subsidiary generated a net operating income of $56,000, compared to a net operating loss of $190,000 in the same period of 2021.

Commercial and developmental highlights

• First PFAS customer – the company recently secured its first PFAS customer. As part of this project, BioLargo will engineer a comprehensive PFAS mitigation plan for an industrial site, and has signed an agreement with a new channel partner to sell the company’s PFAS treatment equipment and engineering services.
• Ikigai’s POOPH – The company’s white-label pet odor control product partnership with Ikigai is advancing well and generating increasing revenues both from manufacturing the product and from license royalties. Sales thus far have exceeded early expectations, and the company’s partners at Ikigai are confident that growth will continue, especially as they push to get the product onto shelves at major retailers.
• Garratt-Callahan partnership – The company expects first sales of the “minimal liquid discharge” (MLD) wastewater treatment equipment developed in partnership with Garratt-Callahan to begin soon, following discussions with an expanding list of Garratt-Callahan customers.
• Larger engineering projects – In this quarter, BioLargo Engineering, Science & Technologies executed engineering projects for new customers, including its project to develop prototypes with Ultra Safe Nuclear, and the waste-to-energy plant project in South America. With both of these projects, early phase work is nearly done, and management anticipates that additional phases will soon begin, with the scope of work and level of engagement expanding.

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as “we believe”. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo Q2 2022 Earnings Results Webcast and Conference Call on Wednesday, August 17, 2022 - 4 PM Eastern Time

Westminster, CA – August 12, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company announced it will host an investor webcast and conference call on Wednesday August 17, 2022, at 1:00 pm Pacific / 4:00 pm Eastern. The event, which will be open to the public, will be held to review the company’s financial results for the three and six months ended June 30, 2022, discuss recent milestones and ongoing business initiatives, and conduct a question-and-answer session.

To listen to a live broadcast, go to the site linked below at least 15 minutes prior to the scheduled start time to register and download any necessary audio/video software.

 

To participate in the live webcast and teleconference:

Webcast Link:	https://www.webcaster4.com/Webcast/Page/2448/46358
Teleconference Domestic:	888-506-0062
Teleconference International: Participant Access Code:	973-528-0011 656092

 

To watch or listen to a replay of the webcast or teleconference:

 

Webcast Replay Expiration:	Thursday, August 17, 2023
Teleconference Replay Expiration:	Wednesday, August 31, 2022
Teleconference Replay Domestic:	877-481-4010
Teleconference Replay International:	919-882-2331
Replay Passcode:	46358

 

The webcast replay and accompanying presentation materials will be made available on the Investor Relations section of BioLargo’s website at www.biolargo.com/investor-relations.

 

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.